The European Parliament yesterday voted towards the adoption of the new Clinical Trials Regulation.
The European Parliament yesterday voted towards the adoption of the new Clinical Trials Regulation, which removes the legal framework for pharma to not publish its data by stating that information from trial study reports should not be considered commercially confidential.
The Regulation also requires, among other things, that
The European pharma industry association, EFPIA, welcomed the vote, but said the Regulation’s revision objectives have been only partially achieved. In a press statement, EFPIA commented: “[It] is critical that the Commission and EMA interpret the Clinical Trial Regulation in a manner that respects patient privacy, the integrity of regulatory decision-making, and incentives for companies to make long-term investments in biomedical research.”
Richard Bergstrom, EFPIA’s Director General, added: “There is still work to be done. The success of this legislation will depend on how it is applied in practice.” For EFPIA, this means how the legislation is implemented at member state level, so that collaboration between ethics committees is promoted and clinical trial applications are assessed in the shortest time possible.
A key pillar of success will be the efficient operation of the EMA’s European Clinical Trials Database, says EFPIA, who are calling for the portal and database to be fully operational within the mandated timeline.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.